David Morrow to Risk Factors
This is a "connection" page, showing publications David Morrow has written about Risk Factors.
Connection Strength
0.075
-
Acute Myocardial Infarction. N Engl J Med. 2017 05 25; 376(21):2053-2064.
Score: 0.022
-
Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic. JAMA Netw Open. 2021 05 03; 4(5):e218828.
Score: 0.007
-
A current review of COVID-19 for the cardiovascular specialist. Am Heart J. 2020 08; 226:29-44.
Score: 0.007
-
Demographics, Care Patterns, and Outcomes of Patients Admitted to Cardiac Intensive Care Units: The Critical Care Cardiology Trials Network Prospective North American Multicenter Registry of Cardiac Critical Illness. JAMA Cardiol. 2019 09 01; 4(9):928-935.
Score: 0.006
-
Derivation and Validation of a Novel Cardiac Intensive Care Unit Admission Risk Score for Mortality. J Am Heart Assoc. 2019 09 03; 8(17):e013675.
Score: 0.006
-
Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial. Vasc Med. 2019 04; 24(2):159-161.
Score: 0.006
-
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. Diabetes Care. 2018 03; 41(3):577-585.
Score: 0.006
-
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation. 2018 02 13; 137(7):684-692.
Score: 0.006
-
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. J Am Heart Assoc. 2017 Oct 24; 6(10).
Score: 0.006
-
Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006 Aug 08; 114(6):550-7.
Score: 0.003
-
Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Am Heart J. 2005 May; 149(5):846-50.
Score: 0.002